{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:35:46Z","timestamp":1793223346147,"version":"4.5.0"},"reference-count":180,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Acute myeloid leukemia (AML) remains a dismal disease with poor prognosis, particularly in the relapsed\/refractory (R\/R) setting. Chimeric antigen receptor (CAR) therapy has yielded remarkable clinical results in other leukemias and thus has, in principle, the potential to achieve similar outcomes in R\/R AML. Redirecting the approved CD19-specific CAR designs against the myeloid antigens CD33, CD123, or CLEC12A has occasionally yielded morphologic leukemia-free states but has so far been marred by threatening myeloablation and early relapses. These safety and efficacy limitations are largely due to the challenge of identifying suitable target antigens and designing adequate receptors for effective recognition and safe elimination of AML. Building on lessons learned from the initial clinical attempts, a new wave of CAR strategies relying on alternative target antigens and innovative CAR designs is about to enter clinical evaluation. Adapted multiantigen targeting, logic gating, and emerging cell engineering solutions offer new possibilities to better direct T-cell specificity and sensitivity toward AML. Pharmacologic modulation and genetic epitope engineering may extend these approaches by augmenting target expression in AML cells or minimizing target expression in normal hematopoietic cells. On\/off switches or CAR T-cell depletion may curb excessive or deleterious CAR activity. Investigation of AML-intrinsic resistance and leukemic microenvironmental factors is poised to reveal additional targetable AML vulnerabilities. We summarize here the findings, challenges, and new developments of CAR therapy for AML. These illustrate the need to specifically adapt CAR strategies to the complex biology of AML to achieve better therapeutic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024063","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T09:32:42Z","timestamp":1733304762000},"page":"1113-1125","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":70,"title":["Honing CAR T cells to tackle acute myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-1456","authenticated-orcid":false,"given":"Sascha","family":"Haubner","sequence":"first","affiliation":[{"name":"1Columbia Initiative in Cell Engineering and Therapy, Department of Medicine, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"2Department of Medicine III, University Hospital, Ludwig Maximilian University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"1Columbia Initiative in Cell Engineering and Therapy, Department of Medicine, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10393","key":"2025031315212063200_bib1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"2025031315212063200_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2025031315212063200_bib3","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.immuni.2023.09.010","article-title":"Synthetic manipulation of the cancer-immunity cycle: CAR-T cell therapy","volume":"56","author":"Singh","year":"2023","journal-title":"Immunity"},{"issue":"177","key":"2025031315212063200_bib4","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"issue":"16","key":"2025031315212063200_bib5","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"224","key":"2025031315212063200_bib6","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"16","key":"2025031315212063200_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025031315212063200_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025031315212063200_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2025031315212063200_bib10","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025031315212063200_bib11","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2025031315212063200_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1189\/jlb.0205096","article-title":"A\u00a0study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing","volume":"79","author":"Hernandez-Caselles","year":"2006","journal-title":"J\u00a0Leukoc Biol"},{"issue":"6","key":"2025031315212063200_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/glycob\/cwq220","article-title":"Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells","volume":"21","author":"Perez-Oliva","year":"2011","journal-title":"Glycobiology"},{"key":"2025031315212063200_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellimm.2018.09.005","article-title":"Expression of IL-3 receptors and impact of IL-3 on human T and B cells","volume":"334","author":"Renner","year":"2018","journal-title":"Cell Immunol"},{"key":"2025031315212063200_bib15","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.2147\/OTT.S205678","article-title":"IFN-gamma and TNF-alpha aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"suppl 1","key":"2025031315212063200_bib16","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial [abstract]","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"issue":"23","key":"2025031315212063200_bib17","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.1073\/pnas.90.23.11137","article-title":"The receptor for interleukin 3 is selectively induced in human endothelial cells by tumor necrosis factor alpha and potentiates interleukin 8 secretion and neutrophil transmigration","volume":"90","author":"Korpelainen","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2025031315212063200_bib18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2025031315212063200_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbrc.2006.11.148","article-title":"CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells","volume":"353","author":"Chang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2025031315212063200_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1096\/fj.07-9435com","article-title":"Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function","volume":"22","author":"Yona","year":"2008","journal-title":"FASEB J"},{"issue":"10","key":"2025031315212063200_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nri3737","article-title":"Siglec-mediated regulation of immune cell function in disease","volume":"14","author":"Macauley","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2025031315212063200_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41598-017-00290-w","article-title":"Evidence for C1q-mediated crosslinking of CD33\/LAIR-1 inhibitory immunoreceptors and biological control of CD33\/LAIR-1 expression","volume":"7","author":"Son","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"2025031315212063200_bib23","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2025031315212063200_bib24","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025031315212063200_bib25","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2025031315212063200_bib26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","article-title":"CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy","volume":"137","author":"Willier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025031315212063200_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"2025031315212063200_bib28","doi-asserted-by":"crossref","first-page":"798087","DOI":"10.3389\/fimmu.2021.798087","article-title":"CD33 delineates two functionally distinct NK cell populations divergent in cytokine production and antibody-mediated cellular cytotoxicity","volume":"12","author":"Hejazi","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"2025031315212063200_bib29","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41375-017-0008-6","article-title":"PI3K orchestration of the in\u00a0vivo persistence of chimeric antigen receptor-modified T cells","volume":"32","author":"Zheng","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2025031315212063200_bib30","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"2025031315212063200_bib31","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","article-title":"Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors","volume":"95","author":"Marin","year":"2010","journal-title":"Haematologica"},{"key":"2025031315212063200_bib32","doi-asserted-by":"crossref","first-page":"683065","DOI":"10.1155\/2012\/683065","article-title":"In\u00a0vitro and in\u00a0vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia","volume":"2012","author":"Dutour","year":"2012","journal-title":"Adv Hematol"},{"issue":"8","key":"2025031315212063200_bib33","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in\u00a0vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2025031315212063200_bib34","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"2025031315212063200_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O'Hear","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"2025031315212063200_bib36","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"24","key":"2025031315212063200_bib37","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl\u00a0Acad Sci U S A"},{"issue":"28","key":"2025031315212063200_bib38","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.9674","article-title":"Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia","volume":"7","author":"Laszlo","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"2025031315212063200_bib39","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"issue":"9","key":"2025031315212063200_bib40","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/s41375-021-01160-1","article-title":"Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy","volume":"35","author":"Godwin","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"2025031315212063200_bib41","doi-asserted-by":"crossref","first-page":"200854","DOI":"10.1016\/j.omton.2024.200854","article-title":"Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy","volume":"32","author":"Fiorenza","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"5","key":"2025031315212063200_bib42","doi-asserted-by":"crossref","first-page":"e009013","DOI":"10.1136\/jitc-2024-009013","article-title":"Developing a membrane-proximal CD33-targeting CAR T cell","volume":"12","author":"Freeman","year":"2024","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2025031315212063200_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2025031315212063200_bib44","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial [abstract]","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025031315212063200_bib45","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2025031315212063200_bib46","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-065X.2012.01164.x","article-title":"The GM-CSF\/IL-3\/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling","volume":"250","author":"Broughton","year":"2012","journal-title":"Immunol Rev"},{"issue":"10","key":"2025031315212063200_bib47","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"2025031315212063200_bib48","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Munoz","year":"2001","journal-title":"Haematologica"},{"issue":"8","key":"2025031315212063200_bib49","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"Testa","year":"2002","journal-title":"Blood"},{"issue":"15","key":"2025031315212063200_bib50","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/bloodadvances.2016002931","article-title":"High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression","volume":"1","author":"Wittwer","year":"2017","journal-title":"Blood Adv"},{"issue":"3","key":"2025031315212063200_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"issue":"18","key":"2025031315212063200_bib52","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T\u00a0cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"Mardiros","year":"2013","journal-title":"Blood"},{"issue":"15","key":"2025031315212063200_bib53","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2025031315212063200_bib54","doi-asserted-by":"crossref","first-page":"e000845","DOI":"10.1136\/jitc-2020-000845","article-title":"41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in\u00a0vivo","volume":"8","author":"Baroni","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2025031315212063200_bib55","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1038\/s41467-022-29668-9","article-title":"Allogeneic TCRalphabeta deficient CAR T-cells targeting CD123 in acute myeloid leukemia","volume":"13","author":"Sugita","year":"2022","journal-title":"Nat Commun"},{"issue":"suppl 1","key":"2025031315212063200_bib56","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial [abstract]","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2025031315212063200_bib57","first-page":"1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells [abstract]","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"2025031315212063200_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03271-5","article-title":"Cytokine-mediated CAR T therapy resistance in AML","author":"Bhagwat","year":"2024;30(12):3697-3708","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2025031315212063200_bib59","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML) [abstract]","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2025031315212063200_bib60","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1074\/jbc.M313127200","article-title":"Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes","volume":"279","author":"Marshall","year":"2004","journal-title":"J Biol Chem"},{"issue":"1","key":"2025031315212063200_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/imr.13174","article-title":"Understanding inhibitory receptor function in neutrophils through the lens of CLEC12A","volume":"314","author":"McLeish","year":"2023","journal-title":"Immunol Rev"},{"issue":"5","key":"2025031315212063200_bib62","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.immuni.2017.04.019","article-title":"Identification of a human clonogenic progenitor with strict monocyte differentiation potential: a counterpart of mouse cMoPs","volume":"46","author":"Kawamura","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"2025031315212063200_bib63","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jcmm.13519","article-title":"Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology","volume":"22","author":"Bill","year":"2018","journal-title":"J\u00a0Cell Mol Med"},{"issue":"22","key":"2025031315212063200_bib64","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1158\/0008-5472.CAN-04-1659","article-title":"C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia","volume":"64","author":"Bakker","year":"2004","journal-title":"Cancer Res"},{"issue":"7","key":"2025031315212063200_bib65","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"2025031315212063200_bib66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","article-title":"Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia","volume":"34","author":"Morsink","year":"2019","journal-title":"Blood Rev"},{"issue":"11","key":"2025031315212063200_bib67","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2025031315212063200_bib68","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"2025031315212063200_bib69","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"2025031315212063200_bib70","doi-asserted-by":"crossref","first-page":"e001229","DOI":"10.1136\/jitc-2020-001229","article-title":"Modulating TNFalpha activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia","volume":"8","author":"Ataca Atilla","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"5","key":"2025031315212063200_bib71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"2025031315212063200_bib72","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","article-title":"HLA-independent T cell receptors for targeting tumors with low antigen density","volume":"28","author":"Mansilla-Soto","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"2025031315212063200_bib73","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00277-024-05617-y","article-title":"Modified EASIX scores predict severe CRS\/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy","volume":"103","author":"Zhao","year":"2024","journal-title":"Ann Hematol"},{"issue":"11","key":"2025031315212063200_bib74","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"issue":"8","key":"2025031315212063200_bib75","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med"},{"issue":"2","key":"2025031315212063200_bib76","first-page":"615","article-title":"Successful application of PD-1 knockdown CLL-1 CAR-T therapy in two AML patients with post-transplant relapse and failure of anti-CD38 CAR-T cell treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am J Cancer Res"},{"key":"2025031315212063200_bib77","doi-asserted-by":"crossref","first-page":"1389227","DOI":"10.3389\/fimmu.2024.1389227","article-title":"Case report: donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed\/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission","volume":"15","author":"Miao","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"2025031315212063200_bib78","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"2","key":"2025031315212063200_bib79","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/geno.2000.6238","article-title":"Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely related to CD97","volume":"67","author":"Lin","year":"2000","journal-title":"Genomics"},{"issue":"8","key":"2025031315212063200_bib80","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2002-11-3540","article-title":"The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans","volume":"102","author":"Stacey","year":"2003","journal-title":"Blood"},{"issue":"suppl 1","key":"2025031315212063200_bib81","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1182\/blood-2018-99-113037","article-title":"Frequency and clinical characteristics associated with putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in acute myeloid leukemia [abstract]","volume":"132","author":"Shahswar","year":"2018","journal-title":"Blood"},{"key":"2025031315212063200_bib82","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.trsl.2019.05.004","article-title":"Characterization of upregulated adhesion GPCRs in acute myeloid leukemia","volume":"212","author":"Yang","year":"2019","journal-title":"Transl Res"},{"issue":"suppl 1","key":"2025031315212063200_bib83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/blood-2023-187045","article-title":"Multimodal atlas of paired diagnosis and relapse AML samples enables novel therapeutic targeting of surface antigens [abstract]","volume":"142","author":"Halfond","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2025031315212063200_bib84","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/0008-5472.CAN-23-2314","article-title":"Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"},{"issue":"4","key":"2025031315212063200_bib85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2025031315212063200_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2025031315212063200_bib87","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune efector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2025031315212063200_bib88","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity (ICAHT): EHA\/EBMT Consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2025031315212063200_bib89","doi-asserted-by":"crossref","first-page":"101826","DOI":"10.1016\/j.xcrm.2024.101826","article-title":"IL-21\/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T\u00a0cell therapy","volume":"5","author":"Rubino","year":"2024","journal-title":"Cell Rep Med"},{"issue":"2","key":"2025031315212063200_bib90","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1182\/blood.V74.2.586.586","article-title":"Interleukin-1 stimulates proliferation of acute myeloblasts leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release","volume":"74","author":"Delwel","year":"1989","journal-title":"Blood"},{"issue":"10","key":"2025031315212063200_bib91","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/sj.leu.2403457","article-title":"Interleukin-1\u03b2 maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways","volume":"18","author":"Turzanski","year":"2004","journal-title":"Leukemia"},{"issue":"13","key":"2025031315212063200_bib92","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","article-title":"Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia","volume":"18","author":"Carey","year":"2017","journal-title":"Cell Rep"},{"issue":"10","key":"2025031315212063200_bib93","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/2159-8290.CD-21-1146","article-title":"The impact of inflammation-induced tumor plasticity during myeloid transformation","volume":"12","author":"Yeaton","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"2025031315212063200_bib94","first-page":"27","article-title":"An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia","volume":"4","author":"Lasry","year":"2023","journal-title":"Nat Cancer"},{"issue":"8","key":"2025031315212063200_bib95","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood.2024024000","article-title":"IL-9 secreted by leukemia stem cells induces Th1-skewed CD4+ T cells, which promote their expansion","volume":"144","author":"Radpour","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2025031315212063200_bib96","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-21-3594","article-title":"Release of IFNgamma by acute myeloid leukemia cells remodels bone marrow immune microenvironment by inducing regulatory T cells","volume":"28","author":"Corradi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025031315212063200_bib97","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00262-023-03594-1","article-title":"Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8(+) clonal effector and CAR T-cell function while promoting a senescence-associated phenotype","volume":"73","author":"Towers","year":"2024","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2025031315212063200_bib98","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s44321-024-00024-2","article-title":"Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells","volume":"16","author":"Mueller","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"4","key":"2025031315212063200_bib99","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2025031315212063200_bib100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"issue":"7","key":"2025031315212063200_bib101","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025031315212063200_bib102","doi-asserted-by":"crossref","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"2025031315212063200_bib103","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","article-title":"Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch","volume":"28","author":"Warda","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"2025031315212063200_bib104","doi-asserted-by":"crossref","first-page":"e004222","DOI":"10.1136\/jitc-2021-004222","article-title":"Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia","volume":"10","author":"Trad","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"2025031315212063200_bib105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41467-022-28243-6","article-title":"CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells","volume":"13","author":"Hebbar","year":"2022","journal-title":"Nat Commun"},{"key":"2025031315212063200_bib106","doi-asserted-by":"crossref","first-page":"928140","DOI":"10.3389\/fcell.2022.928140","article-title":"Chimeric antigen receptor T cells targeting cell surface GRP78 to eradicate acute myeloid leukemia","volume":"10","author":"Yu","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2025031315212063200_bib107","doi-asserted-by":"crossref","first-page":"101422","DOI":"10.1016\/j.xcrm.2024.101422","article-title":"Peptide-scFv antigen recognition domains effectively confer CAR T cell multiantigen specificity","volume":"5","author":"Zoine","year":"2024","journal-title":"Cell Rep Med"},{"issue":"19","key":"2025031315212063200_bib108","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2025031315212063200_bib109","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2025031315212063200_bib110","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"6","key":"2025031315212063200_bib111","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"2025031315212063200_bib112","doi-asserted-by":"crossref","first-page":"101695","DOI":"10.1016\/j.tranon.2023.101695","article-title":"Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape","volume":"34","author":"Xie","year":"2023","journal-title":"Transl Oncol"},{"issue":"2","key":"2025031315212063200_bib113","doi-asserted-by":"crossref","first-page":"200797","DOI":"10.1016\/j.omton.2024.200797","article-title":"CAR\u2019TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment","volume":"32","author":"Teppert","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"1","key":"2025031315212063200_bib114","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejh.14104","article-title":"Tandem bispecific CD123\/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia","volume":"112","author":"Wang","year":"2024","journal-title":"Eur J Haematol"},{"issue":"12","key":"2025031315212063200_bib115","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41551-024-01287-3","article-title":"Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors","volume":"8","author":"James","year":"2024","journal-title":"Nat Biomed Eng"},{"issue":"suppl 1","key":"2025031315212063200_bib116","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2021-149263","article-title":"\u201cIF-Better\u201d gating: combinatorial targeting and synergistic signaling for enhanced CAR T cell efficacy [abstract]","volume":"138","author":"Haubner","year":"2021","journal-title":"Blood"},{"issue":"623","key":"2025031315212063200_bib117","doi-asserted-by":"crossref","first-page":"eabh1962","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"issue":"10","key":"2025031315212063200_bib118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025031315212063200_bib119","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/bloodadvances.2022008762","article-title":"IL3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML","volume":"7","author":"Perriello","year":"2023","journal-title":"Blood Adv"},{"key":"2025031315212063200_bib120","doi-asserted-by":"crossref","first-page":"100751","DOI":"10.1016\/j.omto.2023.100751","article-title":"Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia","volume":"31","author":"Boucher","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"6","key":"2025031315212063200_bib121","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.2023021054","article-title":"A\u00a0dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML","volume":"143","author":"Dao","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025031315212063200_bib122","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s43018-023-00652-6","article-title":"Structural surfaceomics reveals an AML-specific conformation of integrin beta(2) as a CAR T cellular therapy target","volume":"4","author":"Mandal","year":"2023","journal-title":"Nat Cancer"},{"issue":"7952","key":"2025031315212063200_bib123","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"215","key":"2025031315212063200_bib124","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"issue":"3","key":"2025031315212063200_bib125","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ymthe.2021.11.013","article-title":"Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor","volume":"30","author":"Fei","year":"2022","journal-title":"Mol Ther"},{"issue":"5","key":"2025031315212063200_bib126","doi-asserted-by":"crossref","first-page":"114145","DOI":"10.1016\/j.celrep.2024.114145","article-title":"Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits","volume":"43","author":"Frankel","year":"2024","journal-title":"Cell Rep"},{"issue":"591","key":"2025031315212063200_bib127","doi-asserted-by":"crossref","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"issue":"591","key":"2025031315212063200_bib128","doi-asserted-by":"crossref","first-page":"eabd8836","DOI":"10.1126\/scitranslmed.abd8836","article-title":"SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models","volume":"13","author":"Hyrenius-Wittsten","year":"2021","journal-title":"Sci Transl Med"},{"issue":"8","key":"2025031315212063200_bib129","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to\u00a0AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J"},{"key":"2025031315212063200_bib130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol Ther Oncolytics"},{"issue":"8","key":"2025031315212063200_bib131","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/s41375-020-01109-w","article-title":"A\u00a0modular and controllable T cell therapy platform for acute myeloid leukemia","volume":"35","author":"Benmebarek","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"2025031315212063200_bib132","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2025031315212063200_bib133","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"2025031315212063200_bib134","doi-asserted-by":"crossref","first-page":"2003532","DOI":"10.1080\/2162402X.2021.2003532","article-title":"Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting","volume":"10","author":"Seitz","year":"2021","journal-title":"Oncoimmunology"},{"issue":"6","key":"2025031315212063200_bib135","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/s41375-023-01905-0","article-title":"Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML","volume":"37","author":"Nixdorf","year":"2023","journal-title":"Leukemia"},{"issue":"22","key":"2025031315212063200_bib136","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2025031315212063200_bib137","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2023-177867","article-title":"Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy UniCAR-T-CD123 in relapsed\/refractory AML [abstract]","volume":"142","author":"Wermke","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025031315212063200_bib138","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","article-title":"Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents","volume":"26","author":"Riether","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"2025031315212063200_bib139","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00428-024-03741-8","article-title":"Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agents","volume":"485","author":"Marques-Piubelli","year":"2024","journal-title":"Virchows Arch"},{"key":"2025031315212063200_bib140","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2025031315212063200_bib141","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"2025031315212063200_bib142","doi-asserted-by":"crossref","first-page":"1145441","DOI":"10.3389\/fimmu.2023.1145441","article-title":"Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"2025031315212063200_bib143","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/s41375-018-0009-0","article-title":"CAR T-cells targeting FLT3 have potent activity against FLT3(-)ITD(+) AML and act synergistically with the FLT3-inhibitor crenolanib","volume":"32","author":"Jetani","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2025031315212063200_bib144","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12943-022-01541-9","article-title":"A\u00a0novel approach for relapsed\/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv\/NKG2D-CAR T cells and\u00a0gilteritinib","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"issue":"4","key":"2025031315212063200_bib145","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/leu.2008.354","article-title":"Effective in\u00a0vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate","volume":"23","author":"Poggi","year":"2009","journal-title":"Leukemia"},{"key":"2025031315212063200_bib146","doi-asserted-by":"crossref","first-page":"580328","DOI":"10.3389\/fimmu.2020.580328","article-title":"Chimeric antigen receptor T cells targeting NKG2D-ligands show robust efficacy against acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"11","author":"Driouk","year":"2020","journal-title":"Front Immunol"},{"issue":"12","key":"2025031315212063200_bib147","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/cti.2016.73","article-title":"All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"3","key":"2025031315212063200_bib148","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","article-title":"Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2","volume":"33","author":"Humbert","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025031315212063200_bib149","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"714","key":"2025031315212063200_bib150","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"issue":"12","key":"2025031315212063200_bib151","doi-asserted-by":"crossref","first-page":"e20231235","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J\u00a0Exp Med"},{"issue":"7978","key":"2025031315212063200_bib152","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"issue":"11","key":"2025031315212063200_bib153","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.stem.2024.09.003","article-title":"Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia","volume":"31","author":"Ji","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"suppl 1","key":"2025031315212063200_bib154","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2023-190037","article-title":"Trem-cel, a CRISPR\/Cas9 gene-edited allograft lacking CD33, shows rapid primary engraftment with CD33-negative hematopoiesis in patients with high-risk acute myeloid leukemia (AML) and avoids hematopoietic toxicity during gemtuzumab ozogamicin (GO) maintenance post-hematopoietic cell transplant (HCT) [abstract]","volume":"142","author":"DiPersio","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025031315212063200_bib155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/mp.2017.246","article-title":"Markers of microglia in post-mortem brain samples from patients with Alzheimer\u2019s disease: a systematic review","volume":"23","author":"Hopperton","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"9","key":"2025031315212063200_bib156","doi-asserted-by":"crossref","first-page":"e162593","DOI":"10.1172\/JCI162593","article-title":"Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing","volume":"134","author":"Appelbaum","year":"2024","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2025031315212063200_bib157","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"499","key":"2025031315212063200_bib158","doi-asserted-by":"crossref","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"issue":"17","key":"2025031315212063200_bib159","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2025031315212063200_bib160","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","article-title":"Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery","volume":"28","author":"Sommer","year":"2020","journal-title":"Mol Ther"},{"issue":"12","key":"2025031315212063200_bib161","doi-asserted-by":"crossref","first-page":"e0166891","DOI":"10.1371\/journal.pone.0166891","article-title":"In\u00a0vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia","volume":"11","author":"Minagawa","year":"2016","journal-title":"PLoS One"},{"key":"2025031315212063200_bib162","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem\u00a0cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"2025031315212063200_bib163","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41434-023-00404-2","article-title":"RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells","volume":"30","author":"Bouquet","year":"2023","journal-title":"Gene Ther"},{"issue":"13","key":"2025031315212063200_bib164","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","article-title":"Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18","volume":"20","author":"Hu","year":"2017","journal-title":"Cell Rep"},{"issue":"7","key":"2025031315212063200_bib165","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep"},{"issue":"12","key":"2025031315212063200_bib166","doi-asserted-by":"crossref","first-page":"e003894","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"2025031315212063200_bib167","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFNgamma reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"20","key":"2025031315212063200_bib168","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free\u00a0interleukin-18 is elevated in CD22 CAR\u00a0T-cell\u2013associated hemophagocytic lymphohistiocytosis\u2013like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"2025031315212063200_bib169","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1182\/blood.2024024104","article-title":"Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies","volume":"144","author":"Frigault","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2025031315212063200_bib170","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","article-title":"Concurrent transposon engineering and CRISPR\/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells","volume":"24","author":"Gurney","year":"2022","journal-title":"Cytotherapy"},{"issue":"7787","key":"2025031315212063200_bib171","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","article-title":"Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy","volume":"576","author":"Wei","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2025031315212063200_bib172","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"2025031315212063200_bib173","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3892\/mmr.2021.11847","article-title":"Cytotoxic effect of CLL-1 CAR-T cell immunotherapy with PD-1 silencing on relapsed\/refractory acute myeloid leukemia","volume":"23","author":"Lin","year":"2021","journal-title":"Mol Med Rep"},{"issue":"7","key":"2025031315212063200_bib174","doi-asserted-by":"crossref","first-page":"e006857","DOI":"10.1136\/jitc-2023-006857","article-title":"Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia","volume":"11","author":"Wen","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"12","key":"2025031315212063200_bib175","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2023022882","article-title":"Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies","volume":"143","author":"Alvarez Calderon","year":"2024","journal-title":"Blood"},{"issue":"19","key":"2025031315212063200_bib176","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1182\/blood-2011-07-365817","article-title":"Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?","volume":"118","author":"Ustun","year":"2011","journal-title":"Blood"},{"key":"2025031315212063200_bib177","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2019.10.032","article-title":"Blocking\u00a0migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model","volume":"469","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"2025031315212063200_bib178","doi-asserted-by":"crossref","first-page":"1192333","DOI":"10.3389\/fimmu.2023.1192333","article-title":"Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche","volume":"14","author":"Alberti","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"2025031315212063200_bib179","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","article-title":"MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia","volume":"129","author":"Pyzer","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2025031315212063200_bib180","doi-asserted-by":"crossref","first-page":"eadf8522","DOI":"10.1126\/sciadv.adf8522","article-title":"M2 macrophages drive leukemic transformation by imposing resistance to phagocytosis and improving mitochondrial metabolism","volume":"9","author":"Weinhauser","year":"2023","journal-title":"Sci Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/11\/1113\/2359242\/blood_bld-2024-024063-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/11\/1113\/2359242\/blood_bld-2024-024063-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:23:15Z","timestamp":1741864995000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/11\/1113\/534311\/Honing-CAR-T-cells-to-tackle-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":180,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,3,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024063","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}